Scholarlink

<p>The rising incidence of bacterial infections and biofilm development poses considerable issues in healthcare. This work investigates the efficacy of <i>Gymnema sylvestre</i> (GS)-mediated silver nanoparticles (AgNPs) as a possible antibacterial and antibiofilm agent. The GS-AgNPs were effectively synthesized via <i>G. sylvestre</i>, a medicinal plant recognized for its antibacterial attributes, and characterized through UV–visible spectroscopy, SEM–EDX, TEM, and FTIR analysis. The synthesized nanoparticles had a surface plasmon resonance peak at 398&#xa0;nm, validating their production. FTIR spectroscopy elucidated the functional groups implicated in the reduction and stabilization of AgNPs, signifying the existence of biomolecules responsible for nanoparticle synthesis. SEM and TEM micrograph analysis indicated that GS-AgNPs were spherical and polydispersed, with an average size ranging from 50 to 100&#xa0;nm, while EDX analysis verified a significant proportion of silver in the formulation. The antimicrobial efficacy of GS-AgNPs was assessed against <i>Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa,</i> and<i> Staphylococcus aureus</i>, revealing significant antibacterial activity, with the maximum zone of inhibition (19 ± 0.5&#xa0;mm) observed against <i>P. aeruginosa</i> at a concentration of 75&#xa0;µg/mL. Their strong bactericidal action was demonstrated by the MIC values, which ranged from 6.25 to 50&#xa0;µg/mL, and the MBC values, which varied from 12.5 to 100&#xa0;µg/mL. The GS-AgNPs demonstrated substantial biofilm inhibition in a dose-dependent manner, with <i>P. aeruginosa</i> exhibiting 94.6% inhibition, followed by <i>S. aureus</i> at 91.57%, <i>K. pneumoniae</i> at 86.5%, and <i>E. coli</i> at 79.87%. These findings indicate that GS-AgNPs efficiently destroy biofilm matrices and impede bacterial proliferation, presenting a possible remedy for biofilm-related illnesses. The exceptional antibacterial and antibiofilm characteristics of GS-AgNPs highlight their prospective use in biomedical and therapeutic domains, facilitating the advancement of innovative infection control methods. The development of potent antibacterial and antibiofilm drugs for clinical use may result from further investigation and developments in this field.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Enhancing Antibacterial and Antibiofilm Activity Using Gymnema sylvestre Mediated Silver Nanoparticles: A Promising Approach in Infection Control

  • 期刊论文

  • 发表日期：

    2025年5月5日

查看全文
  • G. Keerthiga,
  • R. Sengottuvel,
  • P. C. Obli Prakash,
  • M. Maghimaa

摘要

The rising incidence of bacterial infections and biofilm development poses considerable issues in healthcare. This work investigates the efficacy of Gymnema sylvestre (GS)-mediated silver nanoparticles (AgNPs) as a possible antibacterial and antibiofilm agent. The GS-AgNPs were effectively synthesized via G. sylvestre, a medicinal plant recognized for its antibacterial attributes, and characterized through UV–visible spectroscopy, SEM–EDX, TEM, and FTIR analysis. The synthesized nanoparticles had a surface plasmon resonance peak at 398 nm, validating their production. FTIR spectroscopy elucidated the functional groups implicated in the reduction and stabilization of AgNPs, signifying the existence of biomolecules responsible for nanoparticle synthesis. SEM and TEM micrograph analysis indicated that GS-AgNPs were spherical and polydispersed, with an average size ranging from 50 to 100 nm, while EDX analysis verified a significant proportion of silver in the formulation. The antimicrobial efficacy of GS-AgNPs was assessed against Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Staphylococcus aureus, revealing significant antibacterial activity, with the maximum zone of inhibition (19 ± 0.5 mm) observed against P. aeruginosa at a concentration of 75 µg/mL. Their strong bactericidal action was demonstrated by the MIC values, which ranged from 6.25 to 50 µg/mL, and the MBC values, which varied from 12.5 to 100 µg/mL. The GS-AgNPs demonstrated substantial biofilm inhibition in a dose-dependent manner, with P. aeruginosa exhibiting 94.6% inhibition, followed by S. aureus at 91.57%, K. pneumoniae at 86.5%, and E. coli at 79.87%. These findings indicate that GS-AgNPs efficiently destroy biofilm matrices and impede bacterial proliferation, presenting a possible remedy for biofilm-related illnesses. The exceptional antibacterial and antibiofilm characteristics of GS-AgNPs highlight their prospective use in biomedical and therapeutic domains, facilitating the advancement of innovative infection control methods. The development of potent antibacterial and antibiofilm drugs for clinical use may result from further investigation and developments in this field.